New Treatment Breakthrough for Advanced Hodgkin’s Lymphoma: Opdivo Combination

While Opdivo is not yet FDA-approved for this specific use, experts expect treatment guidelines to be updated soon to recommend nivolumab-AVD as the preferred initial treatment for advanced Hodgkin’s lymphoma

Charles H. Weaver, MD
1–2 minutes
Home » Hodgkins Lymphoma » New Treatment Breakthrough for Advanced Hodgkin’s Lymphoma: Opdivo Combination

In a major development for patients with advanced classic Hodgkin’s lymphoma, a large clinical trial has shown that a new treatment combination is more effective and causes fewer side effects than the current standard therapy. This breakthrough could change the way doctors treat this form of cancer, potentially improving outcomes for thousands of patients. The study, funded by the National Cancer Institute and conducted by the SWOG Cancer Research Network, compared two treatment regimens:

  1. Nivolumab (Opdivo) combined with AVD chemotherapy
  2. The current standard treatment of brentuximab (Adcetris) with AVD chemotherapy

Key Findings

  • After two years, 92% of patients receiving nivolumab-AVD were alive without their cancer progressing, compared to 83% in the brentuximab-AVD group.
  • Patients treated with nivolumab-AVD experienced fewer side effects overall and fewer serious side effects.
  • The new treatment approach nearly eliminated the need for radiation therapy, even in younger patients aged 12-17.

What This Means for Patients

  1. More Effective Treatment: The nivolumab-AVD combination appears to be more successful at eliminating cancer and preventing its return.
  2. Fewer Side Effects: Patients may experience less severe side effects, particularly compared to the intense pain and tingling (peripheral neuropathy) often associated with brentuximab.
  3. Reduced Need for Radiation: This is especially significant for younger patients, as it may help avoid long-term health problems associated with radiation therapy.
  4. Broader Applicability: The study included a diverse group of participants, including adolescents and adults, making the results relevant to a wide range of patients.

While nivolumab is not yet FDA-approved for this specific use, experts expect treatment guidelines to be updated soon to recommend nivolumab-AVD as the preferred initial treatment for advanced Hodgkin’s lymphoma. This new treatment approach offers hope for better outcomes and improved quality of life for patients facing advanced Hodgkin’s lymphoma. As always, patients should discuss their individual treatment options with their healthcare providers.

More Reading

  • Share your experience, ask a question, or start a conversation by joining Cancer Connect.

References:

Herrera AF, LeBlanc M, Castellino SM, et al. Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma. N Engl J Med. 2024 Oct 17;391(15):1379-1389.

Adapted from https://www.cancer.gov/news-events/cancer-currents-blog/2024/hodgkin-lymphoma-nivolumab-avd-first-line?cid=eb_govdel

You May Be Interested In